



Life Science Investor
Konference

Copenhagen

Feb 23 2022

Anders Haegerstrand
CEO

Empowering the body to fight vascular diseases

Company Information in brief



- Publicly-traded; ANNX
- Stockholm-based
- Semi-virtual operations
- 5 employees
- World-leading in Annexin A5
- ANXV a recombinant human Annexin A5
 - First-in-class biologic
 - Broad therapeutic potential
- GMP production completed
- Strong IP
- Clinical Stage
 - First in Human Phase 1 completed Q3 2021



- Ophthalmology
- Retinal Vein Occlusion (RVO) primary indication
- Imaging trial data in Q1 2022
- Phase 2/proof of concept trial in the US planned to start Q1-2 2022

Team

Management



Anders
Haegerstrand
CEO



Anna Frostegård
CSO/CMO



Susan Suchdev
COO



Henrik Palm
CFO

Board of Directors



Gisela Sitbon



Uli Hacksell
Chairman



Lena Torlegård



Carl-Fredrik Lindner



Johan Frostegård
Founder




Mårten Österlund

Annexin A5 - a defence protein


A natural tool for cellular protection and repair

Annexin A5



Highly evolutionary
conserved

Produced by



Blood vessels




Heart

cells with barrier function

Main Target

Phosphatidylserine
a lipid on cell membranes



Dying cell
Stressed cell
Platelets
Exosomes
Microparticles
Modified LDL
Leaking Mitochondriae
Endotoxin/Lipid A

Functions



Commentary

Plasma membrane repair and cellular damage control:
The annexin survival kit



Annette Draeger*, Katia Monastyrskaya, Eduard B. Babiychuk

Department of Cell Biology, Institute of Anatomy, University of Bern, Baltzerstr. 2 3012, Bern, Switzerland

Protective Shield
Band Aid
Emergency/Rescue
Escapetosis
Safeguard
Missile- homing aspect
Bloodhound

Retinal Vein Occlusion

Pathophysiology and clinical presentation



Aggregation of
blood cells in the eye vein

Retinal damage
swelling, bleeding, cell death,
growth of new blood vessels

Impaired vision

Retinal Vein Occlusion

Epidemiology and the current standard of care


- Second most common cause of blindness
- Studies suggest over 16 M are diagnosed with RVO*
- Current treatments are invasive, > 6 monthly intravitreal injections
 - Lucentis®, Eylea®, off-label Avastin®, Ozurdex®
- Only app. 30% of patients experience clinically relevant improvement with current treatments#




Intravitreal injection of anti-VEGF drug.
John T. Thompson, MD. Retina Image Bank, 2017; Image 27125. © American Society of Retina Specialists.
* Market Research Future 2018
#Rogers et al., Ophthalmology

ANXV for Retinal Vein Occlusion


First-in-Class mechanism of action





Externalization of PS on RBCs



RBC adhesion to endothelial cells



Inhibition of RBC adhesion



Journal of Thrombosis and Haemostasis, 9: 1049–1055

DOI: 10.1111/j.1538-7836.2011.04251.x

ORIGINAL ARTICLE

Red blood cell phosphatidylserine exposure is responsible for increased erythrocyte adhesion to endothelium in central retinal vein occlusion

M.-P. WAUTIER,^{*,†,‡,§} E. HÉRON,^{§,†} J. PICOT,^{*,†,‡} Y. COLIN,^{*,†,‡} O. HERMINE[†] and J.-L. WAUTIER^{*,†,‡,§}

^{*}INSERM, UMRS665, Paris; [†]Université Paris Diderot-Paris7, Paris; [‡]Institut National de la Transfusion Sanguine, Paris; [§]Centre Hospitalier National d'Ophthalmologie des Quinze-Vingts, Paris; [¶]Hôpital Necker, Paris; and ^{**}Groupe Hospitalier Lariboisière, Paris, France

Wautier, Heron et al, J Thromb Haemost, 2011

ANXV's unique Modes of Action

	Effects	ANXV	Anti VEGF
1.	Reduces RBC aggregation	✓	✗
2.	Reduces RBC adhesion to endothelium	✓	✗
3.	Anti-thrombotic, local	✓	✗
4.	Anti-inflammatory, local	✓	✗
5.	Anti-apoptotic , local	✓	✗
6.	Repairs cell membranes	✓	✗
7.	Improves circulation, local	Indirectly via 1, 2, 3	✗
8.	Limits retinal area of retinal non perfusion	Indirectly via 5,6,7	Uncertain ¹
9.	Reduces pathologic neoangiogenesis	✓	✓
10.	Reduces macular edema	Indirectly via 7,9	✓

The RVO market



Global Retinal Vein Occlusion Market

The global retinal vein occlusion market was valued at US\$ 15,582.4 Mn in 2020 and is projected to reach US\$ 32,534.8 Mn by 2031, expanding at a CAGR of 7.3% from 2021 to 2031. Rise in prevalence of retinal vein occlusion due to increase in geriatric patient population, high blood pressure, arteriosclerosis, diabetes, and glaucoma, new product launches and high annual cost of therapy (ACOT) drive the global retinal disorders treatment market.

2020A Total Revenue


US\$ 15,582.4 Mn

2031F Total Revenue

US\$ 32,534.8 Mn


% CAGR (2021–2031)

7.3%




Market Share, by Type

2020A




Market Share, by Treatment Type

2020A



Market Share, by Region

2020A



ANXV Clinical Development – Phase I

First in Human clinical trial, ongoing


- First in Human (FiH) clinical trial in healthy volunteers
 - Single and Multiple Ascending Doses (SAD/MAD)
- Phase I FiH completed in Q3 2021
 - *No limiting safety issues reported*
- Data aims to support treatment with ANXV for multiple acute and semi-acute clinical indications



Imaging study with labeled ANXV in RVO

De-risking clinical development

- Fluorescent ANXV to be visualised in the affected eye
- Imaging study in RVO patients underway
 - Tracer B.V. and UMCG Hospital, The Netherlands
 - Imaging specialists and Ophthalmologists
- First data expected Q1 2022
 - Proof of drug delivery to site
 - Dose guidance (PK, PS biomarker)
 - Patient subgroup guidance (onset, site, type)



RVO – key meetings with authorities

Successful outcome of regulatory meetings


- Clear feedback
 - Non-clinical toxicology data package sufficiency
 - Immunogenicity assessment plan
 - Animal data or Phase 1 data do not limit dosing in patients
 - Clinical endpoints and patient selection
 - Standard of care (anti-VEGF) may be delayed during PoC
 - Patient numbers required for registration



Phase 2/Proof of Concept in RVO

De-risking clinical development

- ANXV to improve blood flow and reduce retinal damage in RVO patients
 - Safety and exploratory efficacy study
 - App. 20 patients
 - Adaptive study design
 - Multiple endpoints
- IND approval estimated Q1 2022
 - Expert CRO contracted and clinical sites selected
 - Significant interest among US ophthalmologists



Annexin A5-PS binding in Inflammation and Injury

Labelled Annexin A5 administered to ≈ 400 patients for diagnostic imaging good safety/tolerability

Rheumatoid arthritis

active inflammation in a joint

Radio-labeled Annexin A5 at sites of inflammation (black)




Courtesy Dr. R. Hustinx, Belgium

Atherosclerotic artery

after a “balloon” vascular procedure


Radio-labeled Annexin A5 focal accumulation at sites of damage (black)



Courtesy Prof. C. Reutelingsperger, The Netherlands

ANXV therapeutic opportunities

Broad potential




Niche indications

Retinal Vein Occlusion
Sickle Cell Disease




Cardiovascular Diseases

Acute Coronary Syndrome
Peripheral Arterial Disease



Cancer


Immuno-Oncology



Viral Infections

COVID-19
Ebola

Company Strategy



Thank you!

Empowering the body to fight vascular diseases